ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 612

Long-Term Sustainability of TNF-Blocker Injection Spacing in Rheumatoid Arthritis: Results of a 3-Year Long-Term Observational Follow-up of a Tapering randomised Controlled Trial

Johanna Sigaux1, Florian Bailly2,3, Frédérique Gandjbakhch1,3, Violaine Foltz1,3, Florence Tubach4,5, Laure Gossec1,6 and Bruno Fautrel1,7, 1Rheumatology, Pitié Salpêtrière Hospital, Paris, France, 2rheumatology, Pitié Salpêtrière Hospital, paris, France, 3Sorbonne Universités, UPMC Univ Paris 06, Paris, France, Paris, France, 4Aix-Marseille University, Marseille, France, 5Université Pierre et Marie Curie (UPMC)-Paris 6; APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 7501875013, Paris, France ;, Paris, France, 6Sorbonne Universités, UPMC University Paris 06, Paris, France, Paris, France, 7GRC08, Sorbonne Universités, UPMC Univ Paris 06, Paris, France, Paris, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords:

Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Tapering of TNF blockers (TNFb) in rheumatoid arthritis (RA) patients in sustained remission is feasible in short-term randomized controlled trials (RCT). Less data are available on the sustainability of such a strategy over a longer term in real life settings. The main objective was to assess the probability of sustained dose reduction or discontinuation of TNFb in a 3-year long-term observational follow-up of the Spacing of TNFb injections in Rheumatoid ArthritiS Study (STRASS). This trial compared the effect of progressive spacing of TNF-blocker injections (S arm) to their maintenance (M arm) for patients with established RA in remission for at least 6 months.

Methods: The STRASS investigators of the STRASS trial were contacted between April and October 2015, i.e., 3 years after the end of the trial, to collect evolution data at 1, 2 and 3 years after trial completion of patients having completed the RCT. During this long-term follow-up period, physicians were free to either keep the same regimen as in the arm patients were initially randomized or change injections frequency or drugs. The main endpoints were the rate of patients with spaced TNFb injections, the rate of TNFb-free patients and the mean TNFb dose compared to full dose or dose quotient (as a % of full dose).

Results: Ninety-six patients (76.2% of the completer population) had data available up to 3 years. At this term, mean DAS28 was 2.6±1.3 (respectively 2.7±1.4 in the initial Maintenance-arm, 2.6±1.2 in the initial Spacing-arm, p=0.89) and 72.9% were in low disease activity or remission (respectively 72.1% and 73.0%, p=0.93) (Table 1). Thirty patients (31.2%) had a tapered regimen (respectively 30.8% and 31.8%, p=0.96) and 11.5% (respectively 5.8% and 18.2%, p=0.07) discontinued TNFb (Figure 1). The mean TNFb dose quotient among the 96 patients was 72% of full dose (respectively, 77 and 66%, p=0.16). Eighteen (30.2%) had structural damage progression during the follow-up  (respectively 25.0% and 36.8%).

Conclusion : Sustained TNFb de-escalation (injection tapering or discontinuation) is achievable in only 43% of patients over 3 years with limited dose reduction (28% on average).  More optimal strategies remain needed to durably maintain remission in patients for whom bDMARD have been tapered or discontinued. Table 1 Patient outcome over 3 years of follow up

Baseline

3-year follow-up

Total (n=96) Total  (n=96) Initial M-arm (n=52) Initial S-arm  (n=44)
Disease activity

Tender joint count (28 joints) 2.4±4.9 1.5±2.5 1.8±2.9 1.1±1.9
Swollen joint count (28 joints) 1.0±1.9 1.1±2.5 1.2±2.8 0.9±2.1
ESR, mm/1st hour 15.9±11.7 17.8±15.7 18.8±2.8 16.6±10
CRP, mg/L 3.8±5.2 5.6±12.5 7.4±16,2 3.6±4.6
Normal acute phase reactant , n (%) 59 (61.5) 54 (56.2) 30 (57.7) 24 (54.5)
DAS28 2.4±1.2 2.6±1.3 2.7±16,2 2.63±1.2
bDMARD intake
Any TNFb 82 (85.4) 72 (75.0) 41 (78.8) 31 (70.4)
    ADA, n (%) 35 (36.5) 30 (31.2) 17 (32.7) 13 (29.5)
    ETA, n (%) 47 (48.9) 42 (43.7) 24 (46.1) 18 (40.9)
Other bDMARD, n (%) 2 (2.1) 13 (13.5) 8 (15.4) 5 (11.4)
Full dose, n (%) 60 (62.5) 44 (45.8) 27 (51.9) 17 (38.6)
Tapered regimen, n (%) 21 (21.9) 30 (31.2) 16 (30.8) 14 (21.8)
Discontinuation, n (%) 12 (12.5) 11 (11.5) 3 (5.8) 8 (18.2)
Switch from another bDMARD 4 (4.2) 18 (18.7) 10 (19.2) 8 (18.2)
Dose quotient, mean (sd) 0.75±0.37 0.72±0.36 0.77±0.33 0.66±0.39

  Figure 1 bDMARDs intake over time

Disclosure: J. Sigaux, None; F. Bailly, None; F. Gandjbakhch, None; V. Foltz, None; F. Tubach, None; L. Gossec, None; B. Fautrel, None.

To cite this abstract in AMA style:

Sigaux J, Bailly F, Gandjbakhch F, Foltz V, Tubach F, Gossec L, Fautrel B. Long-Term Sustainability of TNF-Blocker Injection Spacing in Rheumatoid Arthritis: Results of a 3-Year Long-Term Observational Follow-up of a Tapering randomised Controlled Trial [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/long-term-sustainability-of-tnf-blocker-injection-spacing-in-rheumatoid-arthritis-results-of-a-3-year-long-term-observational-follow-up-of-a-tapering-randomised-controlled-trial/. Accessed .

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-sustainability-of-tnf-blocker-injection-spacing-in-rheumatoid-arthritis-results-of-a-3-year-long-term-observational-follow-up-of-a-tapering-randomised-controlled-trial/